Skip to main content
ORTIN GLOBAL LIMITED logo

ORTIN GLOBAL LIMITED — Investor Relations & Filings

Ticker · ORTINGLOBE ISIN · INE749B01020 BSE.NS Manufacturing
Open in API
Filings indexed 203 across all filing types
Latest filing 2026-05-30 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS ORTINGLOBE

About ORTIN GLOBAL LIMITED

https://www.ortinlabsindia.com/

Ortin Global Limited is a pharmaceutical enterprise engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs), intermediates, and finished dosage formulations. The company maintains a diverse product portfolio covering various therapeutic segments, such as anti-diabetics, anti-hypertensives, anti-retrovirals, analgesics, and anti-pyretics. Its operations include the synthesis of complex chemical molecules and the production of oral solids and liquids, including tablets, capsules, and syrups. With a focus on integrated manufacturing processes, the company serves both domestic and international healthcare markets. Ortin Global Limited prioritizes research and development to expand its product offerings and optimize production techniques, ensuring compliance with established quality standards across its manufacturing facilities.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 85% confidence The document is a stock‐exchange filing from Ortin Global Limited providing the outcome of its board meeting and enclosing the audited financial results for the quarter and year ended 31.03.2026. It includes comprehensive financial statements (statement of audited results, assets & liabilities, cash flows) and an auditor’s report—all hallmarks of a quarterly (interim) financial report rather than a short earnings highlight or full annual report. Under the defined categories, this is an Interim / Quarterly Report (IR). FY 2026
2026-05-30 English
Outcome of Board Meeting held on 30.05.2026
Interim / Quarterly Report Classification · 85% confidence The document is a statutory disclosure made under SEBI (LODR) Regulation 33 announcing the audited financial results “for the quarter and year ended 31.03.2026” following a Board meeting. It contains comprehensive financial statements (P&L, balance sheet, cash flow, notes) and the independent auditor’s report. While it covers full‐year audited results, it is not a full Annual Report (10-K) but rather the standalone audited periodical results. This fits the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-30 English
Audited Financial Results along with Audit Report for the Quarter and Year ended 31.03.2026
Interim / Quarterly Report Classification · 82% confidence The document is the formal submission of audited financial results under SEBI (LODR) Regulation 33 for the quarter and year ended March 31, 2026; it contains full financial statements (income statement, balance sheet, cash flows) and the statutory auditor’s report. It is not the full annual report (10-K) or a simple announcement, but rather an interim/quarterly financial report. Therefore, it fits the “Interim / Quarterly Report (IR)” category. FY 2026
2026-05-30 English
Annual Secretarial Compliance Report for the Year ended 31.03.2026
Regulatory Filings Classification · 89% confidence The document is titled “Annual Secretarial Compliance Report” prepared by a Practicing Company Secretary and filed pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations. It is a statutory compliance submission to stock exchanges rather than a financial statement, management discussion, dividend notice, AGM materials, or proxy solicitation. It does not present actual financial results or detailed corporate governance policies but certifies regulatory compliance. Therefore, it belongs to general regulatory filings.
2026-05-28 English
Ortin Global Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve 1. Audited standalone financial ....
Regulatory Filings Classification · 15% confidence The document is a formal intimation to stock exchanges of an upcoming Board of Directors meeting to consider audited results. It does not contain the results themselves, nor a management change, but is a regulatory announcement notifying timing of a board meeting. This falls under general regulatory filings (RNS), as it does not fit other specific categories.
2026-05-25 English
Rarever Financial Advisors Pvt. Ltd. ("Manager to the Offer") has informed BSE as under :"With reference to the captioned subject, Public Announcement dated February 10, 2026, Detailed ....
M&A Activity Classification · 98% confidence The document is a formal notice from the financial advisor to a stock exchange under SEBI takeover regulations announcing the identified date for an open offer by an acquirer to purchase up to 26% of the target company’s shares. This falls squarely under M&A Activity (takeover/open offer) rather than a routine regulatory filing or other category.
2026-05-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.